MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...
Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19. Outcomes of myeloma cast nephropathy in the era of anti-CD38 monoclonal antibody-based frontline ...
Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...
Please provide your email address to receive an email when new articles are posted on . “Teclistamab has already been approved in multiple myeloma, and there is institutional data where it shows that ...
Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load There is consensus that patients with light ...
The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...
Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...
The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results